

Withdrawal

NOTICES

15887

DEPARTMENT OF HEALTH,
EDUCATION, AND WELFARE

Food and Drug Administration

[DESI 6151; Docket No. FDC-D-458; NDA 6-151 etc.]

ROCHE LABORATORIES AND
E. R. SQUIBB & SONS

Certain Preparations Containing Dihyprylone or Pipazethate Hydrochloride; Notice of Withdrawal of Approval of New-Drug Applications

A notice was published in the FEDERAL REGISTER of May 9, 1972 (37 F.R. 9354), extending to each holder of a new-drug application listed below, and to any interested person who may be adversely affected, an opportunity for hearing on the proposal of the Commissioner of Food and Drugs to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), withdrawing approval of each listed application and all amendments and supplements thereto. The basis of the proposed action was the lack of substantial evidence that the drugs are effective for their labeled indications.

NDA No.	Drug	NDA Holder
6-151	Sedulon Syrup containing dihyprylone and extract of thyme.	Roche Laboratories, Division of Hoffman-La Roche Inc., Roche Park, 340 Kingsland St., Nutley, NJ 07110.
12-820	Theratuss Tablets containing pipazethate hydrochloride.	E. R. Squibb & Sons, 909 3d Ave., New York, NY 10022.

Neither the holders of the new-drug applications nor any other interested persons have filed a written appearance of election as provided by said notice. The failure to file such an appearance is construed as an election by such persons not to avail themselves of an opportunity for hearing.

The Commissioner of Food and Drugs, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505 (e), 52 Stat. 1053, as amended; 21 U.S.C. 355(e)), and under authority delegated to him (21 CFR 2.120), finds that on the basis of new information before him with respect to each of said drugs, evaluated together with the evidence available to him when each application was approved, there is a lack of substantial evidence that each of the drugs will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling thereof.

Therefore, pursuant to the foregoing finding, approval of the above-listed, new-drug applications and all amendments and supplements thereto is withdrawn effective on the date of publica-

tion hereof in the FEDERAL REGISTER (8-5-72).

Dated: July 26, 1972.

SAM D. FINE,
Associate Commissioner
for Compliance.

[FR Doc.72-12248 Filed 8-4-72;8:46 am]

[DESI 8881; Docket No. FDC-D-436; NDA 8-881]

USV PHARMACEUTICAL CORP.

Hexamethonium Chloride for Oral Use; Notice of Withdrawal of Approval of New Drug Application

On March 30, 1972, there was published in the FEDERAL REGISTER (37 F.R. 6511) a notice of opportunity for hearing in which the Commissioner of Food and Drugs proposed to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) withdrawing approval of the following new drug application in the absence of substantial evidence that oral forms of hexamethonium chloride will have the antihypertensive effect they purport or are represented to have under the conditions of use prescribed, recommended, or suggested in their labeling.

NDA 8-881; Hexamethonium Chloride Tablets; USV Pharmaceutical Corp., 1 Scarsdale Road, Tuckahoe, NY 10707.

USV Pharmaceutical Corp., by letter of May 15, 1972, elected not to avail itself of the opportunity for a hearing.

The Commissioner of Food and Drugs, pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505(e), 52 Stat. 1053, as amended; 21 U.S.C. 355(e)) and under authority delegated to him (21 CFR 2.120), finds on the basis of new information before him with respect to such drug, evaluated together with the evidence available to him when the application was approved, that there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling thereof.

Therefore, pursuant to the foregoing finding, approval of the above new drug application, and all amendments and supplements thereto, is withdrawn effective on the date of publication hereof in the FEDERAL REGISTER (8-5-72).

Dated: July 26, 1972.

SAM D. FINE,
Associate Commissioner
for Compliance.

[FR Doc.72-12249 Filed 8-4-72;8:46 am]

Office of Education

FUNDING UNDER EMERGENCY
SCHOOL ASSISTANCE PROGRAM

Further Notice of Continuation

Notice was previously published in the FEDERAL REGISTER (July 14, 1972, 37 F.R. 13816) indicating that the Commissioner of Education would consider applications

construction of the 13.2-mile transmission line from the existing Lyman Substation to the proposed Torrington Substation site and the construction of the Torrington Substation. The principal function of the project is to provide adequate additional power to improve the reliability of the existing 34.5-kv system presently serving the city of Torrington (population 4,237) and other municipal and rural loads in the area.

Copies are available from:

Office of Ecology, Room 7620, Bureau of Reclamation, Department of the Interior, Washington, D.C. 20240, Telephone (202) 343-4991.

Division of Engineering Support, E&R Center, Technical Services Branch, Building 67, Denver Federal Center, Denver, Colo. 80225, Telephone (303) 234-3007.

Office of Regional Director, Bureau of Reclamation, Building 20, Denver Federal Center, Denver, Colo. 80225, Telephone (303) 234-4441.

Single copies of the final environmental statement may be obtained on request to the above offices. In addition, copies are available from the National Technical Information Service, Department of Commerce, Springfield, Va. 22151 for \$3 each. Please refer to the statement number above.

Dated: July 31, 1972.

W. W. LYONS,
Deputy Assistant Secretary
of the Interior.

[FR Doc.72-12251 Filed 8-4-72;8:46 am]

DEPARTMENT OF AGRICULTURE

Commodity Credit Corporation

[Amdt. 1]

SALES OF CERTAIN COMMODITIES

Monthly Sales List (Fiscal Year Ending
June 30, 1973)

The CCC Monthly Sales List for the fiscal year ending June 30, 1973, published in 37 F.R. 13352 is amended as follows:

1. The second sentence of section 25 entitled "Rice, Rough—Unrestricted Use Sales—F.O.B. warehouse" is revised to read as follows:

The formula price for August 1972 is the 1972 loan rate plus 5 percent plus 12 cents per hundredweight.

2. The first sentence of section 36 entitled "Cotton, Upland—Unrestricted Use Sales" is revised to read as follows:

Competitive offers under the terms and conditions of Announcement NO-C-33 (Disposition of Upland Cotton—For Unrestricted Use and Under Barter Contracts, as amended).

Effective date: 2:30 p.m., e.d.t., July 31, 1972.

Signed at Washington, D.C., on July 31, 1972.

KENNETH E. FRICK,
Executive Vice President,
Commodity Credit Corporation.

[FR Doc.72-12292 Filed 8-4-72;8:49 am]